donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > NTRA Natera > Financial Statement > Income statement
NTRA Natera
52.030
-0.540-1.03%
Post Mkt Price
52.03000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Total revenue
39.55% 198.2M 27.45% 194.13M 59.97% 625.49M 53.97% 173.03M
Operating revenue
39.55% 198.2M 27.45% 194.13M 59.97% 625.49M 53.97% 173.03M
Cost of revenue
43.52% 109.24M 54.48% 103.22M 56.38% 318.42M 57.18% 94.12M
Gross profit
34.97% 88.96M 6.33% 90.92M 63.87% 307.07M 50.31% 78.91M
Operating expense
28.06% 232.05M 53.55% 228.05M 92.05% 775.24M 72.83% 218.57M
Selling and administrative expenses
17.27% 149.47M 36.28% 147.63M 68.31% 511.03M 56% 146.76M
Research and development costs
53.63% 82.58M 100.09% 80.41M 164.12% 264.21M 121.75% 71.81M
Operating profit
-24.1% -143.09M -117.61% -137.13M -116.47% -468.17M -88.82% -139.67M
Net non-operating interest income expense
-338.78% -2.15M -83.19% -1.29M -10.44% -8.31M -294% -6.31M
Non-operating interest income
-- -- -41.58% 801K -- -- -- --
Non-operating interest expense
3.61% 2.15M 0.68% 2.09M -44.93% 8.31M -51.76% 2.08M
Other net income (expense)
277K 192.01% 5.38M
Special income (charges)
-- -- -- -- -- 0 -- 0
-Gain on sale of business
-- -- -- -- -- 0 -- --
Other non- operating income (expenses)
-- 277K -- -- -- 5.38M -- --
Income before tax
-25.2% -144.96M -117.23% -138.42M -105.14% -471.1M -84.08% -140.59M
Income tax
-20.25% 193K 33.58% 179K 530.61% 618K -185.71% -30K
Net income
-25.1% -145.15M -117.05% -138.6M -105.32% -471.72M -83.96% -140.56M
Net income continuous Operations
-25.1% -145.15M -117.05% -138.6M -105.32% -471.72M -83.96% -140.56M
Minority interest income
Net income attributable to the parent company
-25.1% -145.15M -117.05% -138.6M -105.32% -471.72M -83.96% -140.56M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-25.1% -145.15M -117.05% -138.6M -105.32% -471.72M -83.96% -140.56M
Basic earnings per share
-13.64% -1.5 -95.95% -1.45 -83.45% -5.21 -63.74% -1.49
Diluted earnings per share
-13.64% -1.5 -95.95% -1.45 -83.45% -5.21 -63.74% -1.49
Dividend per share
Currency Unit
USDUSDUSDUSD
Accounting Standards
US-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions
----Unqualified Opinion with Explanation--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company’s algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual’s tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...